A Phase 2 proof-of-concept clinical trial is currently being conducted for postmenopausal women with stress urinary incontinence (SUI), though today’s data is from a preclinical study, modelled using animals.
This study approximates the pelvic floor changes that can be associated with SUI, the company said.
“These results demonstrate the ability of these SARMs to restore the pelvic floor muscles to their normal weight and provide support for a potential role of these compounds in the treatment of SUI,” said Dr Ramesh Narayanan, who is acting as consultant to GTx.
The result is being presented today in New Orleans, at a meeting of the Society of Urodynamics, Female Pelvic Medicine and Urogenital Reconstruction (SUFU).
In its ongoing Phase 2 trial, GTx is evaluating the effects of orally administered enobosarm.